Cholesterol Pharmacology Flashcards

1
Q

Why is cholesterol management important

A

Cholesterol and LDL levels are major risk factors for CVD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are indications for cholesterol pharmacological therapy

A

Primary prevention
Secondary prevention
Of cardiovascular disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Who require statin therapy for primary prevention

A

10yr CV risk >10% on QRISK2 assessment
CKD with eGFR <60
T1DM with: >40yo, >10yrs diabetic, established nephropathy, other CVD risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What treatment is given for primary prevention

A

Artorvastatin 20mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do you screen for hyperlipidaemia

A
Full lipid profile: 
Total cholesterol
HDL
Non-HDL cholesterol 
TAG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Who require treatment for secondary prevention

A

Anyone with established CVD:
IHD
Stroke
Peripheral arterial dienes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What treatment is given for secondary prevention

A

80mg artorvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is mechanism of action of statins

A

Inhibit HMG-CoA reductase
Inhibit cholesterol synthesis at hepatocytes
Reduce LDL synthesis
Increase LDL uptake (low cholesterol in hepatocytes causes increased LDLR expression)

Thus lower serum cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are secondary benefits of statins

A

Anti inflammatory
Reduce plaque formation
Improve endothelial function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are side effects of statins

A

GI disturbance
Myopathy: Muscle aches, myositis, rhabdomyolysis, raised CK
Liver impairment: raised transaminases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are PK properties of statins

A

30-80% absorption
5-30% systemic availability
CYP450 metabolism (some types)
Taken at night: time of cholesterol synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What monitoring is required for statins

A

LFTs

Baseline, 3 monthly, 12 monthly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is mechanism of action of fibrates

A
PPAR alpha agonist 
Stimulate lipoprotein lipase 
Significant Decrease in TAG levels
Mild decrease in LDL
Mild increase in HDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Give examples of fibrates

A

Bezafibrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are indications of fibrates

A

Mixed hyperlipidaemia:
Hyperlipidaemia with low HDL
Hypertriglyceridaemia

Combination with statins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What caution is required when given in combination with statins

A

Increased risk of myopathy, rhabdomyolysis

17
Q

What are side effects of Fibrates

A

GI disturbance
Myopathy
Liver impairment - raised transaminases
Cholelithiasis

18
Q

What are contra indications of fibrates

A

Liver impairment
Renal impairment
Pre existing gall bladder disease

19
Q

What is mechanism of action of Ezetimibe

A

Inhibit cholesterol receptors in enterocytes
Selective inhibition of cholesterol absorption
Reduced intestinal delivery to hepatocytes
Increased LDL R expression by hepatocytes

20
Q

What are indications of Ezetimibe

A

Monotherapy:
statin therapy contraindicated or not tolerated

Combination:
Failed to achieve adequate reduction on statins

21
Q

What are side effects of Ezetimibe

A

GI disturbance headache

22
Q

Give examples of nicotinic acid

A

Niacin

23
Q

What is mechanism of action of niacin

A

Inhibit VLDL release from hepatocytes
Reduced LDL
Increased HDL

24
Q

What are indications of niacin

A

Best agent to raise HDL

25
Q

What are side effects of niacin

A

Flushing, itching
Hepatotoxicity
Activation of peptic ulcer

26
Q

Give examples of PCSK9 Inhibitors

A

Alirocumab

27
Q

What is mechanism of action of PCSK9 Inhibitors

A

Inhibit PCSK9 activity
PCSK9 normally binds to LDL-LDLR complex and promotes destruction than recycling
Thus increase LDLR recycling
Increased LDL uptake by hepatocytes